Communiqués Simulations Plus, Inc.

Actions

SLP

US8292141053

Equipement et technologie médicale avancés

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 13/07/2026			Varia. 5j.	Varia. 1 janv.
18,25 ^USD	+0,05%		-0,60%	+0,11%

09/07	Simulations Plus : repli du bénéfice ajusté au troisième trimestre fiscal malgré une hausse du chiffre d'affaires	MT
09/07	Simulations Plus, Inc. publie ses résultats pour le troisième trimestre et les neuf mois clos le 31 mai 2026	CI

Communiqués

09/07	Simulations Plus: Fiscal Q3 Earnings Snapshot	AQ
09/07	Simulations Plus Reports Third Quarter Fiscal 2026 Financial Results	BU
06/07	Johnson Fistel Investigates Simulations Plus Following Revenue Guidance Cut and Accounting Disclosures	PR
23/06	Simulations Plus Advances Agentic Drug Development with NVIDIA BioNeMo Agent Toolkit	BU
22/06	Simulations Plus (SLP) Investigation: Investors Who Suffered Losses Encouraged to Contact Johnson Fistel	PR
18/06	Simulations Plus Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Simulations Plus, Inc. - SLP	BU
16/06	SLP Stock Alert: Halper Sadeh LLC is Investigating Whether Simulations Plus, Inc. is Obtaining a Fair Price for its Shareholders	BU
09/06	Simulations Plus (SLP) Securities Investigation: Johnson Fistel Reviews Revenue Guidance Cut, $77.2M Impairment Charge, and Auditor Dispute	NE
03/06	Simulations Plus, Inc. (SLP) Investigation: Johnson Fistel Investigates Investor Losses Following Revenue Guidance Cut, Impairment Charge, and Auditor Dispute	NE
02/06	Simulations Plus, Inc. (SLP) Securities Fraud Investigation: Johnson Fistel Investigates Investor Losses Following Revenue Outlook Revision, Impairment Charge, and Auditor Dispute	BU
21/05	Simulations Plus to Participate in the 23rd Annual Craig-Hallum Institutional Investor Conference	BU
06/05	Simulations Plus and NVIDIA Collaborate to Scale GPU-Accelerated, AI-Assisted Modeling Workflows	BU
21/04	Simulations Plus Announces Collaboration with Lonza and U.S. FDA to Advance Predictive Frameworks for Complex Oral Drug Products	BU
20/04	Simulations Plus Expands Global Access to Model-Informed Drug Development Training Through Its 2026 Spring School	BU
09/04	Simulations Plus: Fiscal Q2 Earnings Snapshot	AQ
09/04	Simulations Plus Reports Second Quarter Fiscal 2026 Financial Results	BU
26/03	Simulations Plus Announces Second Quarter Fiscal Year 2026 Earnings and Conference Call Date	BU
26/03	Simulations Plus Announces Strategic Collaboration Programs for AI-Enabled Modeling	BU
03/03	Simulations Plus Convenes Industry and Regulatory Leaders to Define Responsible AI in MIDD	BU
10/02	Simulations Plus Announces Extensions of U.S. FDA and NIEHS Research Collaborations	BU
05/02	Simulations Plus : to Participate in Upcoming Investor Conferences	PU
03/02	Simulations Plus to Participate in Upcoming Investor Conferences	BU
21/01	Simulations Plus Highlights Platform Innovation and Strategic Direction at 2026 Investor Day	BU
08/01	Simulations Plus: Fiscal Q1 Earnings Snapshot	AQ
08/01	Simulations Plus Reports First Quarter Fiscal 2026 Financial Results	BU